Rescue Hearing

Executive Summary

Rescue Hearing is a privately held biotechnology company headquartered in Gainesville, Florida, dedicated to developing gene therapies that address the root causes of genetic hearing loss. Founded in 2018, the company focuses on specific mutations including DFNB8, DFNB16, and USH1B, which collectively represent a significant unmet medical need. By delivering functional copies of the defective genes directly to the inner ear, Rescue Hearing aims to restore hearing rather than merely amplifying sound with conventional devices. Their approach leverages adeno-associated virus (AAV) vectors engineered for safe and durable expression in cochlear hair cells. If successful, these therapies could transform genetic hearing loss from a lifelong disability into a treatable condition, offering the potential for substantial improvement in quality of life for affected individuals. The company is in the preclinical stage, advancing its lead candidate toward investigational new drug (IND)-enabling studies. Key milestones include optimizing vector design, demonstrating efficacy in animal models, and establishing manufacturing processes for clinical-grade material. Rescue Hearing faces typical early-stage risks such as scientific feasibility, regulatory hurdles, and the need for substantial capital to fund clinical trials. However, the growing interest in gene therapy for sensory disorders and the lack of approved treatments for these genetic forms of hearing loss provide a strong rationale for the company's strategy. Near-term catalysts include the completion of IND-enabling studies and potential partnering or financing events to support a first-in-human trial. Investors should monitor progress in preclinical efficacy and safety data, as well as strategic alliances that could validate the platform.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Gene Therapy Candidate (DFNB8 or DFNB16)40% success
• H2 2026Presentation of Preclinical Efficacy Data at Major Conference70% success
• Q4 2026Series A Financing Round50% success